Genome-wide association studies (GWAS) have identified multiple loci associated with plasma lipid concentrations 1-5 . Common variants at these loci together explain <10% of variation in each lipid trait 4,5 . Rare variants with large individual effects may also contribute to the heritability of lipid traits 6,7 ; however, the extent to which rare variants affect lipid phenotypes remains to be determined. Here we show an accumulation of rare variants, or a mutation skew, in GWASidentified genes in individuals with hypertriglyceridemia (HTG). Through GWAS, we identified common variants in APOA5, GCKR, LPL and APOB associated with HTG. Resequencing of these genes revealed a significant burden of 154 rare missense or nonsense variants in 438 individuals with HTG, compared to 53 variants in 327 controls (P = 6.2 × 10 −8 ), corresponding to a carrier frequency of 28.1% of affected individuals and 15.3% of controls (P = 2.6 × 10 −5 ). Considering rare variants in these genes incrementally increased the proportion of genetic variation contributing to HTG.
GWAS have identified novel and known loci associated with population-based plasma lipid concentrations [1] [2] [3] [4] [5] . Despite the robustness of these associations, the proportion of variability explained by GWAS-identified loci is relatively modest, <10% in most studies 4, 5 . Although vastly expanded study sample sizes continue to reveal new associations, each newly associated variant has an incrementally smaller effect size and contributes only marginally to the cumulative variation of each lipid phenotype 6 . This suggests that GWAS of population-based subjects may be reaching the limits of their ability to reveal genetic variation underlying complex traits. A question that has arisen is whether additional forms of genetic variation, such as rare variants with large individual effects, could contribute to the heritability of complex traits such as plasma lipid concentrations 6, 7 . Although the mechanistic basis for the association between lipid traits and most of the common variants discovered in GWAS is still largely unknown, it remains possible that rare variants in GWAS-identified genes may contribute significantly to lipid phenotypes.
Studying subjects at the extremes of a quantitative phenotype distribution has proven useful in identifying functional rare variants [8] [9] [10] [11] [12] .
Using missense-accumulation analysis in genes defined a priori as likely to contain rare variants, studies can statistically quantify a burden of mutations in subjects with severe phenotypes, before functional assessment of each variant. Primary HTG is one such complex polygenic disease, broadly defined by fasting plasma triglyceride concentrations above the ninety-fifth percentile 13 . Resequencing of triglyceride-modulating candidate genes has implicated both common and rare variants in HTG disease pathophysiology 9, [14] [15] [16] ; however, the majority of phenotypic variation underlying severe HTG remains unattributed 17 . Our objectives were (i) to perform an unbiased GWAS of individuals with HTG to identify common variants associated with HTG, and (ii) to resequence coding regions of candidate genes in loci reaching genome-wide significance to evaluate the burden of rare variants in individuals with HTG compared with controls. Here we show that loci found to be associated with HTG by GWAS also harbor a significant excess of rare variants.
In total, 555 individuals with HTG and 1,319 controls were included in two cohorts of the study: the GWAS cohort included 463 affected individuals and 1,197 controls, and the sequencing cohort included 438 affected individuals and 327 controls. Individuals with HTG were unrelated subjects diagnosed with Fredrickson hyperlipoproteinemia Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia l e t t e r s phenotypes 2B (MIM 144250), 3 (MIM 107741), 4 (MIM 144600) or 5 (MIM 144650), ascertained primarily from a single tertiary referral lipid clinic. The mean plasma triglyceride concentration of individuals with HTG was 14.3 mmol l −1 . We chose controls with maximum recorded fasting plasma triglyceride concentrations <2.3 mmol l −1 to exclude undiagnosed HTG. All study subjects were of self-declared European ancestry; subjects deviating from European ancestry as determined by multidimensional scaling using whole-genome SNP data were removed from sequencing analysis (Supplementary Fig. 1 ). As expected, clinical characteristics of individuals with HTG were less favorable than those of controls, with worse lipid profiles and an increased prevalence of type 2 diabetes ( Table 1) .
The HTG phenotype was tested for association with >2.1 million SNPs using an additive multivariate logistic regression model (Supplementary Fig. 2 ). This model appropriately adjusted for sex, body-mass index, diabetes status and ten principal components of ancestry (Supplementary Fig. 3 ). Four loci were associated with HTG (P < 5 × 10 −7 ): APOA5, GCKR, LPL and APOB ( Table 2) . Most associations with HTG were mediated by the same genomic loci associated with fasting plasma triglyceride concentration in population-based GWAS 5 : APOA5 and GCKR were associated at the same lead SNP, and LPL was associated with the same haplotype block. In contrast, the HTG-associated SNPs in APOB were ~123 kb upstream of the gene, which would be consistent with the involvement of regulatory elements in the overexpression of triglyceride-rich lipoproteins in HTG pathophysiology. Investigation of subthreshold association signals did not provide any additional insight into novel HTG-associated genes.
Next, we tested the hypothesis that common genetic variants in remaining known triglyceride-associated loci are similarly associated with HTG 5 . Only three loci were replicated at a Bonferroni-corrected significance threshold of P < 0.005: MLXIPL, TRIB1 and ANGPTL3 ( Table 2 ). Positive replication of these triglyceride-associated loci, combined with trends toward significance at FADS1-FADS2-FADS3 (P = 0.05) and NCAN-CILP2-PBX4 (P = 0.07), suggest that additional triglyceridemodulating loci may also be involved in HTG pathophysiology; however, smaller effect sizes probably limit their detection.
We next hypothesized that HTG-associated genes would harbor rare variants related to HTG disease causation. The protein-coding sequences of APOA5, GCKR, LPL and exons 26 and 29 (67.8%) of APOB were resequenced in individual subjects as the regions most likely to harbor protein-compromising mutations. Across the four genes, 80 distinct rare variants were identified with minor allele frequencies <1% in controls ( Fig. 1 and Supplementary Table 1) . A significant accumulation of rare variants was identified in individuals with HTG ( Table 3) , including 154 total variants in 438 HTG diploid genomes, compared to 53 total variants in 327 control diploid genomes (P = 6.2 × 10 −8 ), corresponding to a significantly higher carrier frequency of 28.1% in individuals with HTG compared to 15.3% in controls (P = 2.6 × 10 −5 ). A more restricted analysis of rare variants found exclusively in either individuals with HTG or controls, deliberately removing all reported variants without demonstrated functional compromise, similarly revealed a significant burden of 47 variants in affected individuals, compared to nine variants in controls (P = 2.4 × 10 −5 ); this corresponds to a significantly higher carrier frequency of 10.3% in individuals with HTG compared to 2.8% in controls (P = 4.4 × 10 −5 ). The fasting plasma triglyceride concentrations of carriers with HTG ranged from 3.10 to 88.5 mmol/l, whereas those of control carriers ranged from 0.45 to 1.93 mmol/l. No associations were discerned between such attributes as the gene, mutation type or mutation position and the plasma triglyceride concentration or HTG phenotype.
The strength of association between HTG and genomic loci did not predict the mutation accumulation observed in the resequenced genes. LPL harbored the largest relative proportion of rare variants, followed by GCKR, APOB and APOA5; these had, respectively, 30.9, 10.7, 9.3 and 4.5 rare variants per kilobase of coding sequence in individuals with HTG, and 5.6, 2.7, 4.3 and 0.9 rare variants per kilobase of coding sequence in controls. The burden of rare variants found in individuals with HTG is highly suggestive of phenotype causation, an idea supported by several truncation mutations, in silico predictions of deleterious effects, and bona fide characterized deleterious mutations (Supplementary Table 1 ). The majority Chr., chromosome; CI, confidence interval; MAF, minor allele frequency; OR, odds ratio. Association was tested using an additive multivariate logistic regression model, with sex, body-mass index, diabetes status and ten principal components of ancestry entered as covariates. The top four loci surpassed a prespecified threshold for genome-wide significance of P < 5 × 10 −7 . Remaining loci were replicated from GWAS meta-analysis of population-based triglyceride concentrations 5 .
l e t t e r s of subjects carried only one rare variant; however, subjects with multiple rare variants were also significantly over-represented among individuals with HTG (6.6% of carriers among affected individuals compared with 0.9% of carriers among controls; P = 3.7 × 10 −5 ). Any given rare variant in affected individuals is not necessarily sufficient to cause HTG, but rare variants probably contribute to the biochemical heterogeneity observed among affected people. For instance, the APOB R3500W variant causes hypercholesterolemia 18 , but we found it in an individual with Fredrickson hyperlipoproteinemia phenotype 2B, defined by both plasma triglyceride and total cholesterol in excess of the ninety-fifth percentile. For this individual, APOB R3500W is more likely contributing to the elevated total cholesterol phenotype, but the mutation is a part of his genetic background that led to his ascertainment through the lipid clinic. This person exemplifies our working hypothesis that both common and rare genetic determinants in triglyceride-associated genes together contribute to the phenotypic heterogeneity underlying HTG. Finally, we assessed the contribution of genetic and clinical variables to the total variation in HTG diagnosis, using the individuals included in both the GWAS and resequencing cohorts. A comprehensive logistic regression model including clinical variables and both common and rare genetic variants explained 41.6% of total variation in HTG diagnosis: clinical variables explained 19.7%, common genetic variants in seven HTG-associated loci explained 20.8%, and rare genetic variants in four HTG-associated loci explained 1.1%. These data suggest that rare variants found in four GWAS-identified genes incrementally contribute to the unexplained genetic variation contributing to HTG pathophysiology.
In summary, we performed a GWAS and resequencing of HTGassociated genes and found a significant accumulation of missense and nonsense mutations that contribute to the unexplained genetic component of HTG. Our results suggest that a complex genetic architecture of both common and rare variants in a spectrum of triglyceride-associated genes is responsible for HTG. Future studies using high-throughput next-generation sequencing are required to determine whether these associations extend to additional HTGassociated genes, including MLXIPL, TRIB1 and ANGPTL3, and to triglyceride-associated genes identified by epidemiological-scale GWAS of population-based samples. It also remains possible that rare variants in triglyceride-modulating genes that have not yielded signals in GWAS, such as GPIHBP1 or LMF1, will further contribute to HTG phenotypes 19, 20 . Functional analyses may more accurately define the extent of dysfunction of rare variants identified in individuals with HTG and their role in disease causation, and higher-level analyses, including studies of gene-gene and gene-environment interactions, l e t t e r s will determine the combined impact of multiple genetic variants on plasma triglyceride concentration in individuals with HTG. Our study shows that an accumulation of rare variants is present in GWASidentified genes and that these contribute to the heritability of complex traits among individuals at the extreme of a lipid phenotype.
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MeTHodS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/. Genome-wide association study. All subjects were genotyped using Affymetrix Genome-Wide Human SNP Array 6.0 according to protocols of the London Regional Genomics Centre or the Broad Institute. Imputation was conducted using HapMap CEU phased haplotypes in MACH 23 . All genotypes were filtered for minor allele frequency >1%, Hardy Weinberg P > 0.0001, and 95% call rate or imputation quality r 2 > 0.4. Identity-by-state calculations, multidimensional scaling and association testing were conducted in PLINK 24 . Genome-wide significance was prespecified as P < 5 × 10 −7 ; nominal significance for replication of known triglyceride-associated SNPs was a Bonferroni-corrected threshold P < 0.005. Covariates entered into all analyses included sex, body-mass index, diabetes status and ten principal components of ancestry as generated by Eigenstrat 25, 26 .
Sequencing and mutation accumulation. All genes were bidirectionally sequenced in individual samples using an ABI 3730 Automated DNA Sequencer and called using automated software (Applied Biosystems). Rare variants were manually curated, confirmed by repeat analysis and annotated in silico for functional effects using PolyPhen. Rare variants were defined as having minor allele frequencies <1% in controls. Carriers were defined as having at least one rare variant. Rare-variant accumulation was compared between individuals with HTG and controls using Fisher's exact test, with nominal significance defined as a two-sided P < 0.05. All subjects in the resequencing cohort were sequenced fully across the translated coding sequences of APOA5 (NCBI NG_015894.1 and NP_443200.2), GCKR (NM_001486.3 and NP_001477.2), LPL (NG_008855.1 and NP_000228.1), and exons 26 and 29 of APOB (NG_011793.1 and NP_000375.2) (67.8%). Subjects missing sequencing data in any one gene were removed before analysis. Our intention was to identify rare missense and nonsense variants potentially responsible for HTG disease causation; accordingly, we excluded intronic variants, UTR variants and synonymous variants from mutation-accumulation analyses. Controls were population-based and not phenotypically selected on the basis of extremely low plasma triglyceride concentration; thus, they do not represent a supernormal control group in which protective rare variants would be enriched upon resequencing. Exclusive variants were defined as rare variants found exclusively in individuals with HTG or in controls (not both), with deliberate exclusion of variants previously reported without demonstrated functional compromise. Mutation-accumulation analyses compared either the number of observed rare alleles with the number of reference alleles, or the number of rare-variant carriers with the number of noncarriers, in individuals with HTG and controls.
Genetic variation explained. Subjects included in this analysis were common to both GWAS and resequencing cohorts. The proportion of genetic variation explained was calculated from the residuals of a multivariate logistic regression model, using discrete case-control status as the dependent variable, with a published SAS version 9.2 macro written for this purpose 27 . Independent variables included the clinical covariates age, sex, body-mass index and diabetes status as either continuous or discrete variables, common variants as continuous variables of HTG risk-associated alleles at each of the seven HTG-associated loci, and rare variants as a continuous variable including the number of rare variants carried by each subject.
